Cardiff Oncology reported positive Phase II data for onvansertib in RAS‑mutated metastatic colorectal cancer but the company simultaneously announced the resignations of CEO Mark Erlander and CFO James Levine, triggering a sharp selloff that wiped roughly half of market value. The board named interim CEO Mani Mohindru and promoted a finance veteran to chief accounting officer while hunting for permanent executives. Analysts said the surprise leadership change during a development inflection raises execution risk for planned Phase III strategies and late‑stage financing. Investors reacted to the governance shift even though the clinical readout suggested advancement toward larger trials.